Minoryx

News
Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

Minoryx is a clinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPARγ agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other CNS diseases such as Friedreich’s ataxia.